1. In Vivo
  2. >>Innovation

Making The Most Of A Maturing Myriad Genetics

 
• By Mark Ratner

Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.

For almost a generation, Myriad Genetics Inc. benefited from being the only company to test for BRCA1 and 2 gene mutations, whose presence correlates with the risk of breast and ovarian cancer. The US Supreme Court dissolved that rare monopoly in 2013, when it invalidated some of the company’s crucial patents. Whether in anticipation of such a ruling or not, by then, Myriad had begun developing a more complex predictive cancer test panel that looks at a much greater number of genes. It also had jettisoned a fruitless drug discovery business in 2009, which had been a drain on its cash. Perceived as conservative and reactionary – and mean-spirited in its longstanding assertions of exclusivity to BRCA genes and the data on hereditary breast and ovarian cancer its BRACAnalysis test generated – the company had plans to evolve.

Since 2009, Myriad has tested the acquisition waters, repeatedly repurchased stock, and until recently, watched its revenues climb steadily while...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

BioBytes: AI-Related Deals In Q3 ‘25

 
• By David Wild

The third quarter of 2025 included a host of venture financings for AI-focused biotechs and several $1bn+valued alliances.

ALS Drug Development Case Studies: MediciNova And Coya Therapeutics

 
• By David Wild

MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.

Beyond Data Sharing: How Biopharma Is Rewriting The Rules Of Collaboration

 
• By David Wild

Pharmaceutical companies are creating collaborative AI platforms that simulate drug trials, accelerate discovery and democratize access to proprietary datasets.

How 250 Million Protein Measurements Could Transform Neurodegeneration Drug Development

 
• By Joanne Shorthouse

A massive new proteomics dataset promises to accelerate target identification, biomarker discovery and precision medicine approaches in Alzheimer's, Parkinson's and other neurodegenerative diseases.

More from In Vivo

Too Big To Refill? Pharma’s Race To Replace $300bn In Expiring Revenues

 
• By Daniel Chancellor

An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.

Beyond Cebranopadol: Tris Pharma’s 25-Year Legacy In Drug Delivery Innovation

 
• By David Wild

Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.

Beyond Data Sharing: How Biopharma Is Rewriting The Rules Of Collaboration

 
• By David Wild

Pharmaceutical companies are creating collaborative AI platforms that simulate drug trials, accelerate discovery and democratize access to proprietary datasets.